384 related articles for article (PubMed ID: 23446043)
1. 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing.
Longati P; Jia X; Eimer J; Wagman A; Witt MR; Rehnmark S; Verbeke C; Toftgård R; Löhr M; Heuchel RL
BMC Cancer; 2013 Feb; 13():95. PubMed ID: 23446043
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma: Characterization in a 3D-cell culture model.
Gagliano N; Celesti G; Tacchini L; Pluchino S; Sforza C; Rasile M; Valerio V; Laghi L; Conte V; Procacci P
World J Gastroenterol; 2016 May; 22(18):4466-83. PubMed ID: 27182158
[TBL] [Abstract][Full Text] [Related]
3. Multiplex quantitative analysis of stroma-mediated cancer cell invasion, matrix remodeling, and drug response in a 3D co-culture model of pancreatic tumor spheroids and stellate cells.
Hwang HJ; Oh MS; Lee DW; Kuh HJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):258. PubMed ID: 31200779
[TBL] [Abstract][Full Text] [Related]
4. Comparing in vitro cytotoxic drug sensitivity in colon and pancreatic cancer using 2D and 3D cell models: Contrasting viability and growth inhibition in clinically relevant dose and repeated drug cycles.
Tidwell TR; Røsland G; Tronstad KJ; Søreide K; Hagland HR
Cancer Med; 2024 Jun; 13(11):e7318. PubMed ID: 38872378
[TBL] [Abstract][Full Text] [Related]
5. Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment.
Wong CW; Han HW; Tien YW; Hsu SH
Biomaterials; 2019 Aug; 213():119202. PubMed ID: 31132644
[TBL] [Abstract][Full Text] [Related]
6. Stratified 3D Microtumors as Organotypic Testing Platforms for Screening Pancreatic Cancer Therapies.
Monteiro MV; Gaspar VM; Mendes L; Duarte IF; Mano JF
Small Methods; 2021 May; 5(5):e2001207. PubMed ID: 34928079
[TBL] [Abstract][Full Text] [Related]
7. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
[TBL] [Abstract][Full Text] [Related]
8. 3D-spheroids: What can they tell us about pancreatic ductal adenocarcinoma cell phenotype?
Gagliano N; Sforza C; Sommariva M; Menon A; Conte V; Sartori P; Procacci P
Exp Cell Res; 2017 Aug; 357(2):299-309. PubMed ID: 28571915
[TBL] [Abstract][Full Text] [Related]
9. Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma.
Abou Ali E; Bordacahar B; Mestas JL; Batteux F; Lafon C; Camus M; Prat F
PLoS One; 2018; 13(12):e0209094. PubMed ID: 30596678
[TBL] [Abstract][Full Text] [Related]
10. Establishment and Analysis of a 3D Co-Culture Spheroid Model of Pancreatic Adenocarcinoma for Application in Drug Discovery.
Meier-Hubberten JC; Sanderson MP
Methods Mol Biol; 2019; 1953():163-179. PubMed ID: 30912022
[TBL] [Abstract][Full Text] [Related]
11. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
Schuth S; Le Blanc S; Krieger TG; Jabs J; Schenk M; Giese NA; Büchler MW; Eils R; Conrad C; Strobel O
J Exp Clin Cancer Res; 2022 Oct; 41(1):312. PubMed ID: 36273171
[TBL] [Abstract][Full Text] [Related]
12. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism.
Ibello E; Saracino F; Delle Cave D; Buonaiuto S; Amoroso F; Andolfi G; Corona M; Guardiola O; Colonna V; Sainz B; Altucci L; De Cesare D; Cobellis G; Lonardo E; Patriarca EJ; D'Aniello C; Minchiotti G
J Exp Clin Cancer Res; 2024 Jun; 43(1):165. PubMed ID: 38877560
[TBL] [Abstract][Full Text] [Related]
14. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
15. Generation of an in vitro 3D PDAC stroma rich spheroid model.
Ware MJ; Keshishian V; Law JJ; Ho JC; Favela CA; Rees P; Smith B; Mohammad S; Hwang RF; Rajapakshe K; Coarfa C; Huang S; Edwards DP; Corr SJ; Godin B; Curley SA
Biomaterials; 2016 Nov; 108():129-42. PubMed ID: 27627810
[TBL] [Abstract][Full Text] [Related]
16. Application of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance model.
Yeon SE; No da Y; Lee SH; Nam SW; Oh IH; Lee J; Kuh HJ
PLoS One; 2013; 8(9):e73345. PubMed ID: 24039920
[TBL] [Abstract][Full Text] [Related]
17. Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance.
Lee JH; Kim SK; Khawar IA; Jeong SY; Chung S; Kuh HJ
J Exp Clin Cancer Res; 2018 Jan; 37(1):4. PubMed ID: 29329547
[TBL] [Abstract][Full Text] [Related]
18. Morphological and cytoskeletal changes of pancreatic cancer cells in three-dimensional spheroidal culture.
Matsuda Y; Ishiwata T; Kawamoto Y; Kawahara K; Peng WX; Yamamoto T; Naito Z
Med Mol Morphol; 2010 Dec; 43(4):211-7. PubMed ID: 21267697
[TBL] [Abstract][Full Text] [Related]
19. Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs.
Brumskill S; Barrera LN; Calcraft P; Phillips C; Costello E
J Physiol Biochem; 2023 Feb; 79(1):223-234. PubMed ID: 34865180
[TBL] [Abstract][Full Text] [Related]
20. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance.
Meng Q; Liang C; Hua J; Zhang B; Liu J; Zhang Y; Wei M; Yu X; Xu J; Shi S
Theranostics; 2020; 10(9):3967-3979. PubMed ID: 32226532
[No Abstract] [Full Text] [Related]
[Next] [New Search]
